Dragonboat Biopharmaceutical Company Limited

This phase 2 trial tests an experimental drug called LDP, an anti-PD-L1 monoclonal antibody that helps the immune system attack cancer cells. It enrolls adults with muscle-invasive bladder cancer, non-clear cell kidney cancer, or advanced penile cancer. Participants receive LDP i…

This early-stage trial is testing a combination of two lab-made antibodies in people with advanced solid tumors that have not responded to standard treatments. One antibody (LDP) aims to reactivate the immune system against cancer, while the other (CDP1) blocks a growth signal on…

This study tests a new drug called CDP1, which is a biosimilar (a close copy) of the approved cancer drug cetuximab. The trial enrolls adults with advanced colorectal cancer or head and neck squamous cell carcinoma that has not responded to prior treatments. Researchers compare h…

This early-stage trial tests a new drug called LDP, an antibody that blocks PD-L1, a protein cancers use to hide from the immune system. The study enrolls adults with advanced malignant tumors who have exhausted standard treatments. Researchers are evaluating the drug's safety, t…

This early-stage trial tested a new drug called CDP1, which is a close copy of the cancer drug Erbitux, in 84 healthy male volunteers. The goal was to see how the body handles CDP1, whether it causes side effects, and if it triggers an immune response. The results will help decid…